PowerPoint Presentation

GLOBAL HEAD AND NECK CANCER

THERAPEUTICS MARKET

2016 – 2026

MARKET INTELLIGENCE . CONSULTING

www.techsciresearch.com

MARKET FORECAST & OPPORTUNITIES

Scope of Report

Product of Interest (POI): Head and Neck Cancer Therapeutics

Review Period

2016 – 2019

Base Year

2020

Estimated Year

2021

Forecast Period

2022 – 2026

Year Range

DIAGNOSTIC METHODS

REGION

North America

Europe

APAC

South America

Middle East & Africa

Biopsy

Imaging

Endoscopy

Others

Head and neck cancer is a term used to define cancer that develops in the mouth, throat, nose, salivary glands, oral cancers or other areas of the head and neck. Most of these cancers are squamous cell carcinomas, or cancers that begin in the lining of the mouth, nose and throat.

Market Segmentation

DISEASE INDICATION

Lip and Oral Cavity Cancer

Laryngeal Cancer

Oropharyngeal Cancer

Salivary Gland Cancer

Nasopharyngeal Cancer

Hypopharyngeal Cancer

Surgery

Radiation Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

TREATMENT TYPE

ROUTE OF ADMINISTRATION

THERAPEUTIC CLASS

END USER

Injectable

Oral

PD Inhibitors

EGFR Inhibitors

Microtubule Inhibitors

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

‹#›

Table of Contents

S. No.ContentsPage No.1.Product Overview (A brief description of the category and product inclusions considered under the scope of the study to give clear picture to the client about the product of interest.)2.Research Methodology (A detailed methodology on how we have derived the market related information and what are the measures that has been taken to validate the data.)3.Executive Summary4.Voice of Customer5.Global Head and Neck Cancer Therapeutics Market Outlook, 2016-2026F (This chapter includes a brief overview of the product of interest market such as total market’s growth rate, expected growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of a qualitative information about the market.)5.1.Market Size & Forecast5.1.1.By Value5.2.Market Share & Forecast5.2.1.By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)5.2.2.By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)5.2.3.By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)5.2.4.By Route of Administration (Injectable, Oral)5.2.5.By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)5.2.6.By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)5.2.7.By Company (2020)5.2.8.By Region5.3.Product Market Map

‹#›

Table of Contents

S. No.ContentsPage No.6.Asia-Pacific Head and Neck Cancer Therapeutics Market Outlook6.1.Market Size & Forecast6.1.1.By Value6.2.Market Share & Forecast6.2.1.By Diagnostic Methods6.2.2.By Treatment Type6.2.3.By Disease Indication6.2.4.By Route of Administration6.2.5.By Therapeutic Class6.2.6.By End-User6.2.7.By Country6.3.Asia-Pacific: Country Analysis6.3.1.China Head and Neck Cancer Therapeutics Market Outlook6.3.1.1.Market Size & Forecast6.3.1.1.1.By Value6.3.1.2.Market Share & Forecast6.3.1.2.1.By Diagnostic Methods 6.3.1.2.2.By Treatment Type6.3.1.2.3.By Disease Indication6.3.1.2.4.By Route of Administration6.3.1.2.5.By Therapeutic Class6.3.1.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.6.3.2.India Head and Neck Cancer Therapeutics Market Outlook6.3.2.1.Market Size & Forecast6.3.2.1.1.By Value6.3.2.2.Market Share & Forecast6.3.2.2.1.By Diagnostic Methods 6.3.2.2.2.By Treatment Type6.3.2.2.3.By Disease Indication6.3.2.2.4.By Route of Administration6.3.2.2.5.By Therapeutic Class6.3.2.2.6.By End-User6.3.3.Japan Head and Neck Cancer Therapeutics Market Outlook6.3.3.1.Market Size & Forecast6.3.3.1.1.By Value6.3.3.2.Market Share & Forecast6.3.3.2.1.By Diagnostic Methods 6.3.3.2.2.By Treatment Type6.3.3.2.3.By Disease Indication6.3.3.2.4.By Route of Administration6.3.3.2.5.By Therapeutic Class6.3.3.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.6.3.4.South Korea Head and Neck Cancer Therapeutics Market Outlook6.3.4.1.Market Size & Forecast6.3.4.1.1.By Value6.3.4.2.Market Share & Forecast6.3.4.2.1.By Diagnostic Methods 6.3.4.2.2.By Treatment Type6.3.4.2.3.By Disease Indication6.3.4.2.4.By Route of Administration6.3.4.2.5.By Therapeutic Class6.3.4.2.6.By End-User6.3.5.Australia Head and Neck Cancer Therapeutics Market Outlook6.3.5.1.Market Size & Forecast6.3.5.1.1.By Value6.3.5.2.Market Share & Forecast6.3.5.2.1.By Diagnostic Methods 6.3.5.2.2.By Treatment Type6.3.5.2.3.By Disease Indication6.3.5.2.4.By Route of Administration6.3.5.2.5.By Therapeutic Class6.3.5.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.6.3.6.Singapore Head and Neck Cancer Therapeutics Market Outlook6.3.6.1.Market Size & Forecast6.3.6.1.1.By Value6.3.6.2.Market Share & Forecast6.3.6.2.1.By Diagnostic Methods 6.3.5.2.2.By Treatment Type6.3.6.2.3.By Disease Indication6.3.6.2.4.By Route of Administration6.3.6.2.5.By Therapeutic Class6.3.6.2.6.By End-User7.Europe Head and Neck Cancer Therapeutics Market Outlook7.1.Market Size & Forecast7.1.1.By Value7.2.Market Share & Forecast7.2.1.By Diagnostic Methods7.2.2.By Treatment Type7.2.3.By Disease Indication7.2.4.By Route of Administration7.2.5.By Therapeutic Class7.2.6.By End-User7.2.7.By Country

‹#›

Table of Contents

S. No.ContentsPage No.7.3.Europe: Country Analysis7.3.1.France Head and Neck Cancer Therapeutics Market Outlook7.3.1.1.Market Size & Forecast7.3.1.1.1.By Value7.3.1.2.Market Share & Forecast7.3.1.2.1.By Diagnostic Methods 7.3.1.2.2.By Treatment Type7.3.1.2.3.By Disease Indication7.3.1.2.4.By Route of Administration7.3.1.2.5.By Therapeutic Class7.3.1.2.6.By End-User7.3.2.Germany Head and Neck Cancer Therapeutics Market Outlook7.3.2.1.Market Size & Forecast7.3.2.1.1.By Value7.3.2.2.Market Share & Forecast7.3.2.2.1.By Diagnostic Methods7.3.2.2.2.By Treatment Type7.3.2.2.3.By Disease Indication7.3.2.2.4.By Route of Administration7.3.2.2.5.By Therapeutic Class7.3.2.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.7.3.3.United Kingdom Head and Neck Cancer Therapeutics Market Outlook7.3.3.1.Market Size & Forecast7.3.3.1.1.By Value7.3.3.2.Market Share & Forecast7.3.3.2.1.By Diagnostic Methods 7.3.3.2.2.By Treatment Type7.3.3.2.3.By Disease Indication7.3.3.2.4.By Route of Administration7.3.3.2.5.By Therapeutic Class7.3.3.2.6.By End-User7.3.4.Italy Head and Neck Cancer Therapeutics Market Outlook7.3.4.1.Market Size & Forecast7.3.4.1.1.By Value7.3.4.2.Market Share & Forecast7.3.4.2.1.By Diagnostic Methods 7.3.4.2.2.By Treatment Type7.3.4.2.3.By Disease Indication7.3.4.2.4.By Route of Administration7.3.4.2.5.By Therapeutic Class7.3.4.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.7.3.5.Spain Head and Neck Cancer Therapeutics Market Outlook7.3.5.1.Market Size & Forecast7.3.5.1.1.By Value7.3.5.2.Market Share & Forecast7.3.5.2.1.By Diagnostic Methods 7.3.5.2.2.By Treatment Type7.3.5.2.3.By Disease Indication7.3.5.2.4.By Route of Administration7.3.5.2.5.By Therapeutic Class7.3.5.2.6.By End-User8.North America Head and Neck Cancer Therapeutics Market Outlook8.1.Market Size & Forecast8.1.1.By Value8.2.Market Share & Forecast8.2.1.By Diagnostic Methods8.2.2.By Treatment Type8.2.3.By Disease Indication8.2.4.By Route of Administration8.2.5.By Therapeutic Class8.2.6.By End-User8.2.7.By Country

‹#›

Table of Contents

S. No.ContentsPage No.8.3.North America: Country Analysis8.3.1.United States Head and Neck Cancer Therapeutics Market Outlook8.3.1.1.Market Size & Forecast8.3.1.1.1.By Value8.3.1.2.Market Share & Forecast8.3.1.2.1.By Diagnostic Methods 8.3.1.2.2.By Treatment Type8.3.1.2.3.By Disease Indication8.3.1.2.4.By Route of Administration8.3.1.2.5.By Therapeutic Class8.3.1.2.6.By End-User8.3.2.Mexico Head and Neck Cancer Therapeutics Market Outlook8.3.2.1.Market Size & Forecast8.3.2.1.1.By Value8.3.2.2.Market Share & Forecast8.3.2.2.1.By Diagnostic Methods 8.3.2.2.2.By Treatment Type8.3.2.2.3.By Disease Indication8.3.2.2.4.By Route of Administration8.3.2.2.5.By Therapeutic Class8.3.2.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.8.3.3.Canada Head and Neck Cancer Therapeutics Market Outlook8.3.2.1.Market Size & Forecast8.3.2.1.1.By Value8.3.2.2.Market Share & Forecast8.3.2.2.1.By Diagnostic Methods 8.3.2.2.2.By Treatment Type8.3.2.2.3.By Disease Indication8.3.2.2.4.By Route of Administration8.3.2.2.5.By Therapeutic Class8.3.2.2.6.By End-User9.South America Head and Neck Cancer Therapeutics Market Outlook9.1.Market Size & Forecast9.1.1.By Value9.2.Market Share & Forecast9.2.1.By Diagnostic Methods9.2.2.By Treatment Type9.2.3.By Disease Indication9.2.4.By Route of Administration9.2.5.By Therapeutic Class9.2.6.By End-User9.2.7.By Country

‹#›

Table of Contents

S. No.ContentsPage No.9.3.South America: Country Analysis9.3.1.Brazil Head and Neck Cancer Therapeutics Market Outlook9.3.1.1.Market Size & Forecast9.3.1.1.1By Value9.3.1.2.Market Share & Forecast9.3.1.2.1.By Diagnostic Methods 9.3.1.2.2.By Treatment Type9.3.1.2.3.By Disease Indication9.3.1.2.4.By Route of Administration9.3.1.2.5.By Therapeutic Class9.3.1.2.6.By End-User9.3.2.Argentina Head and Neck Cancer Therapeutics Market Outlook9.3.2.1.Market Size & Forecast9.3.2.1.1By Value9.3.2.2.Market Share & Forecast9.3.2.2.1.By Diagnostic Methods 9.3.2.2.2.By Treatment Type9.3.2.2.3.By Disease Indication9.3.2.2.4.By Route of Administration9.3.2.2.5.By Therapeutic Class9.3.2.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.9.3.3.Colombia Head and Neck Cancer Therapeutics Market Outlook9.3.3.1.Market Size & Forecast9.3.3.1.1By Value9.3.3.2.Market Share & Forecast9.3.3.2.1.By Diagnostic Methods 9.3.2.2.2.By Treatment Type9.3.2.2.3.By Disease Indication9.3.2.2.4.By Route of Administration9.3.2.2.5.By Therapeutic Class9.3.2.2.6.By End-User10.Middle East & Africa Head and Neck Cancer Therapeutics Market Outlook10.1.Market Size & Forecast10.1.1.By Value10.2.Market Share & Forecast10.2.1.By Diagnostic Methods10.2.2.By Treatment Type10.2.3.By Disease Indication10.2.4.By Route of Administration10.2.5.By Therapeutic Class10.2.6.By End-User10.2.7.By Country

‹#›

Table of Contents

S. No.ContentsPage No.10.3.Middle East & Africa : Country Analysis10.3.1.South Africa Head and Neck Cancer Therapeutics Market Outlook10.3.1.1.Market Size & Forecast10.3.1.1.1.By Value10.3.1.2.Market Share & Forecast10.3.1.2.1.By Diagnostic Methods 10.3.1.2.2.By Treatment Type10.3.1.2.3.By Disease Indication10.3.1.2.4.By Route of Administration10.3.1.2.5.By Therapeutic Class10.3.1.2.6.By End-User10.3.2.Saudi Arabia Head and Neck Cancer Therapeutics Market Outlook10.3.2.1.Market Size & Forecast10.3.2.1.1.By Value10.3.2.2.Market Share & Forecast10.3.2.2.1.By Diagnostic Methods10.3.2.2.2.By Treatment Type10.3.2.2.3.By Disease Indication10.3.2.2.4.By Route of Administration10.3.2.2.5.By Therapeutic Class10.3.2.2.6.By End-User

‹#›

Table of Contents

S. No.ContentsPage No.10.3.3.UAE Head and Neck Cancer Therapeutics Market Outlook10.3.3.1.Market Size & Forecast10.3.3.1.1.By Value10.3.3.2.Market Share & Forecast10.3.3.2.1.By Diagnostic Methods 10.3.3.2.2.By Treatment Type10.3.3.2.3.By Disease Indication10.3.3.2.4.By Route of Administration10.3.3.2.5.By Therapeutic Class10.3.3.2.6.By End-User11.Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market12.Clinical Trial Analysis13.Market Dynamics13.1.Drivers13.2.Challenges14.Market Trends & Developments (This section captures recent trends pertaining to manufacturing or consumption, market movements in terms of points of production and consumption, advancements anddevelopment)15.Competitive Landscape

‹#›

Table of Contents

S. No.ContentsPage No.15.1.Competition Outlook15.2.Company Profiles (Top 10 Companies)15.2.1.Company Details15.2.2Products & Services15.2.3.Financials (As Reported)15.2.4.Key Market Focus & Geographical Presence15.2.5.Recent Developments15.2.6.Key Management Personnel16.Strategic Recommendations (Based on the findings of the report strategic recommendations on how to enter and expand market share)17.About Us & Disclaimer

‹#›

RESEARCH METHODOLOGY

Research Methodology

Identifying Key Opinion Leaders

Questionnaire Design

In-depth Interviews

Data Collection

Developing list of respondents

Formulating Questionnaire

Market Profiling

Data Validation

Data Analysis

In-depth secondary research was conducted to determine top players in the global head and neck cancer therapeutics market, overall market size and segmental market size.

In order to conduct industry experts’ interviews, TechSci formulated a detailed discussion guide.

List of industry players and industry specialists was developed.

TechSci conducted interviews with industry experts and industry players for data collection and verification.

Data obtained as a result of primary and secondary research was validated through rigorous triangulation.

The data was scrutinized using MS-Excel, statistical tools and internal proprietary database to obtain qualitative and quantitative insights about the global head and neck cancer therapeutics market

Data

Collection

Data Filter

& Analysis

Research &

Intelligence

Actionable

Insights

Business

Solution

Primary Research

Desk Research

Company Analysis

Recent Developments

Market Changing Aspects/Dynamics

Government Policies

Final Conclusion

Market Participants

Key Strengths

LinkedIn

TechSci Internal Database

Factiva

Hoovers

Paid Sources

Company Website

Company Annual Reports

White Paper Study

Financial Reports

Investor Presentations

Regulatory Body

Associations, etc.

Secondary Research

Primary Research

‹#›

Research Methodology

Baseline Methodology

Our dedicated team of industry experts has monitored and analyzed various aspects of global head and neck cancer therapeutics market. The team has analyzed the outlook of various segments of this market, while considering the major influencing factors such as rising patient pool suffering from head and neck cancer around the world and speculated a positive growth during the next 5 years. The study includes market forecasting, which would enable our clients to take better decisions while planning their strategy to achieve sustainability in global head and neck cancer therapeutics market.

Methodology Followed for Calculation of Market Size:

Market Size by Value: Market size, in terms of value, for the year 2020 was calculated based on information collected through exhaustive secondary research and primary surveys, with various key opinion leaders/stakeholders, such as head and neck cancer therapeutics companies, channel partners, market influencers & end users, industry experts, and other industry participants.

The team interviewed more than 15 – 20 head and neck cancer therapeutics companies, 45 – 50 channel partners, 80 – 100 end users, and 15 – 20 Industry experts and other value chain stakeholders in global head and neck cancer therapeutics market to obtain the overall market size from 2016-2020, which was validated by the Delphi technique. Taking standard deviation into consideration, the market size was averaged out, to arrive at the market size data from 2016-2020.

‹#›

Research Methodology

Respondents were asked about the current and future market growth rates, market shares by diagnostic methods, by treatment type, by disease indication, by route of administration, by therapeutic class, by end user, by company and by region. Removing the outlier responses, the geometric mean of growth estimates and supplier wise revenue shares generated across various segments were considered, to arrive at the final revenue shares. Revenue shares generated across various segments were further triangulated from other stakeholders depending upon the type of head and neck cancer therapeutics.

Methodology Followed for Calculation of Market Shares:

Market shares by diagnostic methods, by treatment type, by disease indication, by route of administration, by therapeutic class, by end user, by company and by region were calculated based on the responses received through primary surveys with industry experts, in which the respondents were asked about the market shares or revenue generated from various type of head and neck cancer therapeutics. The final shares were calculated by taking the geometric mean of the responses gathered from key opinion leaders after eliminating the outliers.

Methodology Followed for Forecasting:

TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in SPSS/Tableau Software.

Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast global head and neck cancer therapeutics market, TechSci Research used various forecast techniques such as:

Moving Average

Time Series Analysis

Regression Analysis

Econometric and Judgmental Analysis

‹#›

Research Methodology

TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research also used the impact analysis during short, medium and long term period to estimate the demand and to reach accurate market numbers. It should be noted that the figures compiled are only for the organized market including market share data.

Partial List of Companies Interviewed Key Secondary SourcesAstraZeneca Plc.Astellas Pharma Inc.AB Science SABristol-Myers Squibb CompanyBoston Biomedical, Inc.Eli Lilly and CompanyF. Hoffmann-La Roche Ltd. (Genentech, Inc.,)Fresenius Medical Care AG & Co. KGaASun Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries LimitedMerck & Co., Inc.Pfizer Inc.Sanofi S.A.Bayer AGAbbVie Inc.World BankTechSci Research Proprietary Database & Knowledge RepositoryCompany Annual Reports Industry MagazinesIndustry ReportsNews Dailies

‹#›

Industry Brief

According to TechSci Research report, “Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral), By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres, Others), By Region, Forecast & Opportunities, 2026”, the market is anticipated to witness a robust CAGR of 7.71% during the forecast period. The growth in global head and neck cancer therapeutics market can be attributed to rising prevalence of head and neck cancer around the world and growing geriatric population, which is more vulnerable to cancer. At present, more than 43 products are undergoing clinical trials for the head and neck cancer therapeutics market. In some cases, early diagnosed cancers are curable but the treatment varies on the basis of extent, location and type of the disease. Latest advances in surgical techniques and nonsurgical therapies such as targeted therapy and immunotherapy aid in preserving the quality of life while offering the most effective care. Apart from this, technological advancements in the screening procedure for cancer and various pipeline drugs such as Atezolizumab, Erlotinib, Ipilimumab, Durvalumab, Avelumab, Afatinib, Bevacizumab, and others will have a positive impact on the market which will further drive the market growth.

Moreover, governments and private organizations’ initiative to provide improved healthcare service and beneficial healthcare reforms are supporting the growth of the global head and neck cancer therapeutics market. Also, growing popularity of immunotherapy for head and neck cancer treatment is expected to provide huge growth opportunities for pharmaceutical companies. Furthermore, cancer awareness programs and early cancer diagnosis are acting as some other key growth drivers for head and neck cancer therapeutics market.

The global head and neck cancer therapeutics market is segmented based on diagnostic methods, treatment type, disease indication, route of administration, therapeutic class, end user and region. Based on disease indication, the market can be segmented into laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer and others. Among them, lip and oral cavity cancer is expected to contribute largest share through 2026 due to a large patient pool affected by lip and oral cancer globally.

Based on therapeutic class, global head and neck cancer therapeutics market can be segmented into PD inhibitors, microtubule inhibitors and EGFR inhibitors. Among them, PD inhibitor drug class is expected to grow significantly during the forecast period owing to new product launches.

Major players operating in the global head and neck cancer therapeutics market include AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Bayer AG and AbbVie Inc. The players are undergoing extensive R&D activities to develop new therapeutic drugs and increase their global market share.

“North America is expected to contribute to the largest share in the global head and neck cancer therapeutics market as United States is witnessing high prevalence HPV-induced cancers. However, Asia Pacific is expected to register fastest CAGR during the forecast period owing to rising incidences of head & neck cancer. The risk factors such as increase in cigarette smoking and usage of tobacco is also making the region a lucrative market for drug manufacturing companies,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

‹#›

23

Sample Data - Snapshot

CAGR By Value

XX%

CAGR By Value

YY%

Global Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016–2026F

Europe Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016–2026F

Germany Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016–2026F

‹#›

24

By Value (USD Million)

201620202021E2026F56789101112131415

Surgery

201620172018201920202021E2022F2023F2024F2025F2026F0.20.20.20.20.20.20.20.20.20.20.2Radiation Therapy

201620172018201920202021E2022F2023F2024F2025F2026F0.20.20.20.20.20.20.20.20.20.20.2Chemotherapy

201620172018201920202021E2022F2023F2024F2025F2026F0.20.20.20.20.20.20.20.20.20.20.2Immunotherapy

201620172018201920202021E2022F2023F2024F2025F2026F0.20.20.20.20.20.20.20.20.20.20.2Targeted Therapy

201620172018201920202021E2022F2023F2024F2025F2026F0.20.20.20.20.20.20.20.20.20.20.2

Biopsy

201620172018201920202021E2022F2023F2024F2025F2026F0.250.250.250.250.250.250.250.250.250.250.25Imaging

201620172018201920202021E2022F2023F2024F2025F2026F0.250.250.250.250.250.250.250.250.250.250.25Endoscopy

201620172018201920202021E2022F2023F2024F2025F2026F0.250.250.250.250.250.250.250.250.250.250.25Others

201620172018201920202021E2022F2023F2024F2025F2026F0.250.250.250.250.250.250.250.250.250.250.25

Report Ordering

Report Name: GLOBAL HEAD AND NECK CANCER THERAPEUTICS MARKET

MARKET FORECAST & OPPORTUNITIES

2016 – 2026

To View Sample OR Purchase Report

 

License Type Price Single User License$4450Multi-User License$5450Custom Research License$9450

‹#›

25

About Us & Disclaimer

TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in number of areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality reports. The proprietary forecasting models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country, regional and global industry prospects. Combined with the detailed analysis of company activity and industry trends, the result is a uniquely rich evaluation of the opportunities available in the market.

Related Reports

Global CT Scanners Market By Slice (8-slice, 16-slice, 32-slice, 64-slice, 128-slice & above), By Modality (Fixed v/s Mobile), By Device Architecture (O-arm v/s C-arm), By Application (Cardiology, Oncology, Neurology, Others), By End Users (Hospitals, Diagnostic Centers, Others), By Region, Competition Forecast & Opportunities, 2026.

Global Connected Drug Delivery Devices Market By Product Type (Connected Sensors v/s Integrated Connected Devices) By Technology (Bluetooth, Near Field Communication, Others) By Application (Asthma & COPD, Diabetes, Others) By End User (Healthcare Providers v/s Homecare) By Region, Competition Forecast & Opportunities, 2026.

The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely, accurate or complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers reliable and first hand. However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.

TechSci Research – North America

708 Third Avenue, Manhattan,

New York, United States

Tel: +1- 646- 360- 1656

Email: sales@techsciresearch.com www.techsciresearch.com

Disclaimer

TechSci Research – Europe

54, Old brook, Bretton,

Peterborough,

United Kingdom

Email: sales@techsciresearch.com www.techsciresearch.com

TechSci Research – Asia-Pacific

B – 44, Sector – 57, Noida, National Capital Region, U.P. - India

Tel: +91-120-4523900

Email: sales@techsciresearch.com www.techsciresearch.com

26